Managing risks: successful clinical development in asthma


Asthma is a complex and heterogeneous disease. Patients experience wheezing, shortness of breath, and coughing, frequently occurring during the night or early morning. The condition is characterised by a range of clinical and pathogenic features including variable and recurring symptoms of airflow obstruction, bronchial hyperresponsiveness, mucus hypersecretion, and underlying pulmonary inflammation. The challenges are further exacerbated by the fact that symptoms of asthma can be non-specific and varied. This spectrum of causes and presentations can make the clinical development of new asthma treatments challenging.

How to read this journal article 

Thank you for visiting Regulatory Rapporteur. Journal articles are restricted to registered users and TOPRA members.

Already a member or have an account? Sign in.

Members login

Included with TOPRA membership

Already a TOPRA member?

Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.



Free access to selected content

Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.

  • Create your own library to save your favourite content.
  • Sign up for Regulatory Rapporteur email newsletters.
Create a free account


TOPRA membership

Become a TOPRA member and join our global community of regulatory affairs professionals.

  • Great savings on our events and training.
  • Be part of our dynamic international community.
  • Contribute to the profession.
  • Grow your skills and knowledge.
  • Take your career to the next level.
Become a member